Key Takeaways
- PLTR shares declined approximately 4.8% to roughly $127.88 on Wednesday, halting a seven-session rally that had delivered 25% gains.
- A Financial Times article highlighted potential risks from Democratic lawmakers who may scrutinize Palantir’s federal contracts.
- Federal contract revenue reached nearly $2.2 billion in the 12 months since Trump’s return to the presidency, representing a 65% annual increase.
- The stock continues trading beneath both its 100-day and 200-day moving averages, with a Death Cross pattern still active since February.
- Wall Street maintains a Buy consensus with a $174.10 average price target; upcoming earnings are anticipated around August 3.
Palantir Technologies (PLTR) shares experienced a significant pullback Wednesday, abruptly ending a week-long surge. The data analytics firm’s stock retreated approximately 4.8% to close at $127.88, ranking among the S&P 500’s poorest performers for the session.
Palantir Technologies Inc., PLTR
The decline followed publication of a Financial Times piece detailing internal company concerns and highlighting the possibility that Democratic legislators might leverage subpoena authority to investigate Palantir’s government engagements should they reclaim House majority control.
DA Davidson’s Gil Luria told Barron’s the price movement appears clearly connected to that article. However, Luria challenged the political risk argument, emphasizing that Palantir has maintained Department of Defense relationships spanning five different administrations from both major parties.
“Each successive administration has expanded their reliance on Palantir’s capabilities beyond what came before,” Luria noted.
The timing carries significance. PLTR had concluded Tuesday’s trading session precisely at its 50-day moving average near $134. Wednesday’s reversal indicates the stock encountered resistance at that technical threshold before retreating.
Palantir declined to provide comment when contacted.
Congressional Risk and Federal Contracts
The political dimension isn’t a fresh development, but the FT piece brought it into sharper focus. Palantir has faced ongoing criticism regarding its engagements with U.S. immigration authorities, military agencies, and operations connected to Israel’s Gaza conflict.
What intensifies the concern now is the revenue volume at risk. The firm secured approximately $2.2 billion in federal contract income during the 12-month period after Trump returned to the White House — representing a 65% increase year-over-year. Commercial sales more than doubled during the same timeframe.
Any interruption to these government agreements would constitute a material business impact, extending beyond mere headline concerns.
Investor Michael Burry has established a short position against PLTR, contending that Anthropic is encroaching on Palantir’s artificial intelligence domain. CEO Alex Karp has rejected this assessment, maintaining that large language models generate challenges that Palantir specifically helps clients address.
Technical Analysis of PLTR
The broader chart structure remains challenged. PLTR currently trades 18.6% beneath its 200-day moving average of $157.31 and 7.9% under its 100-day moving average of $139.05. A Death Cross formation — where the 50-day crosses below the 200-day — emerged in February and persists.
Palantir shares have declined 29% in 2026 and remain 39% off their all-time closing peak of $207.18 reached on November 3, 2025.
The recent seven-day advance had provided temporary reprieve. Following a June 25 trough at $107.27, PLTR surged 25% across seven consecutive sessions. The momentum stemmed partly from an announced collaboration with Nvidia to develop specialized AI frameworks for federal agencies, combined with DA Davidson’s upgrade to Buy with a $175 target.
Wednesday’s selloff halted that momentum entirely.
The next significant milestone arrives with the company’s quarterly results, projected for August 3. Wall Street anticipates earnings per share of 33 cents, up from 16 cents year-ago, alongside revenue of $1.81 billion versus $1.00 billion in the comparable prior-year period.
Analyst consensus supports a Buy recommendation with a mean price objective of $174.10.


